Proliferative Diabetic Retinopathy Pipeline Insight
DelveInsight’s, “Proliferative Diabetic Retinopathy – Pipeline Insight, 2021” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Proliferative Diabetic Retinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Proliferative Diabetic Retinopathy Understanding
Proliferative Diabetic Retinopathy: Overview
Diabetic retinopathy arises from the complication of diabetes and is a serious condition related to sight. The disease is classified into two types- no proliferative and proliferative diabetic retinopathy. Proliferative diabetic Retinopathy is the advanced form of this disease. In the advanced form, the retina is deprived of oxygen due to problems in circulation of blood. To compensate for this, new blood vessels start to form in the retina and into the vitreous. The newly-formed blood vessels may lead to clouded vision as there are chances of blood leakage into the vitreous. If left untreated, PDR may even lead to severe vision loss and eventually blindness.
Proliferative diabetic neuropathy does not have any particular symptoms but some might experience floaters in vision, fluctuation vision, blurred vision, dark or empty areas in the vision, and may even experience vision loss in advanced stage.
Diagnosis of proliferative diabetic retinopathy is done by carrying out a comprehensive dilated eye exam in which various parameters are studied such as retinal detachment, abnormal blood vessels, bleeding in the vitreous, among others. Tests such as optical coherence tomography and fluorescein angiography may also be done.
In case of Proliferative Diabetic Retinopathy, conducting a surgery is the best suitable option. Depending upon the problems with the retina, some other treatments can include vitrectomy, photocoagulation, panretinal photocoagulation, and injecting VEGF inhibitors into the eye.
The companies and academics are working to assess challenges and seek opportunities that could influence Proliferative Diabetic Retinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Proliferative Diabetic Retinopathy.
Proliferative Diabetic Retinopathy Emerging Drugs Chapters
This segment of the Proliferative Diabetic Retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Proliferative Diabetic Retinopathy Emerging Drugs
Emixustat hydrochloride: Kubota Vision
Kubota Vision’s Emixustat hydrochloride is being developed by the company for the treatment of PDR. The drug is designed to modulate the metabolic burden if the eye by modulating the visual cycle activity of the eye. The drug aims to reduce the retina’s oxygen demand which may ultimately slow down the disease progression. It is currently in the phase II stage of drug development.
Further product details are provided in the report……..
Proliferative Diabetic Retinopathy: Therapeutic Assessment
This segment of the report provides insights about the different Proliferative Diabetic Retinopathy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Proliferative Diabetic Retinopathy
There are approx. 4+ key companies which are developing the therapies for Proliferative Diabetic Retinopathy. The companies which have their Proliferative Diabetic Retinopathy drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Kubota Vision and others.
DelveInsight’s report covers around 4+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Proliferative Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Proliferative Diabetic Retinopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Proliferative Diabetic Retinopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proliferative Diabetic Retinopathy drugs.
Proliferative Diabetic Retinopathy Report Insights
- Proliferative Diabetic Retinopathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Proliferative Diabetic Retinopathy Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Proliferative Diabetic Retinopathy drugs?
- How many Proliferative Diabetic Retinopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Proliferative Diabetic Retinopathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Proliferative Diabetic Retinopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Proliferative Diabetic Retinopathy and their status?
- What are the key designations that have been granted to the emerging drugs?